Chiroscience Chirocaine
Executive Summary
Company submitted levobupivacaine NDA April 29 for local, regional, epidural and spinal anesthesia in surgical and obstetric procedures, and as an epidural infusion for post-surgical and intractable pain, alone or in combination with morphine, fentanyl or clonidine. Pediatric dosing information is included in the submission. The NDA is the first submitted in U.S. for the Cambridge, U.K. company. Zeneca has rights to market Chirocaine in the U.S and abroad, except for Japan...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth